如何治疗乳房植入物相关间变性大细胞淋巴瘤
乳房植入物相关间变性大细胞淋巴瘤(BIA-ALCL)是一种新近被世界卫生组织正式认定的T细胞非霍奇金淋巴瘤,多表现为植入物周围迟发性血清肿,几乎均与毛面假体相关。本文作者分享其多学科团队诊疗建议,与NCCN共识指南一致,强调局限期完全手术切除是重要治疗环节。
要点
- BIA-ALCL多表现为乳房植入物周围迟发性血清肿,几乎均与毛面假体相关。
- 局限期BIA-ALCL的治疗中完全手术切除是重要组成部分。
- 作者建议采用多学科团队方法进行诊断、检查和治疗,与NCCN共识指南一致。
核心结论
- BIA-ALCL预后较许多其他系统性T细胞淋巴瘤亚型好;与其他非霍奇金淋巴瘤不同,局限期完全手术切除是患者管理的重要部分。
研究设计与样本
- 本文为作者分享BIA-ALCL诊断、检查和治疗的多学科团队建议,与NCCN共识指南一致;原文未报告系统检索范围或样本量。
主要发现
- BIA-ALCL最常表现为乳房植入物周围迟发性血清肿,几乎均为毛面表面,可表现为乳房疼痛、肿胀或不对称、包膜挛缩,也可表现为乳房肿块和淋巴结受累。
关键数值与推荐
- 原文未报告具体诊断标准数值、推荐等级或给药方案。
临床怎么用
- 作者建议采用多学科团队方法诊断、检查和治疗BIA-ALCL,与NCCN共识指南一致;局限期完全手术切除是管理的重要部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently described form of T-cell non-Hodgkin lymphoma now formally recognized by the World Health Organization classification of lymphoid neoplasms. The disease most often presents with a delayed seroma around the breast implant, almost exclusively with a textured surface, and manifests with breast pain, swelling or asymmetry, capsular contracture, but can also present with a breast mass, and lymph node involvement. The prognosis of BIA-ALCL is favorable compared with many other subtypes of systemic T-cell lymphoma; however, unlike other non-Hodgkin lymphomas, complete surgical excision for localized disease is an important part of the management of these patients. In this paper, we share our recommendations for a multidisciplinary team approach to the diagnosis, workup, and treatment of BIA-ALCL in line with consensus guidelines by the National Comprehensive Cancer Network.
引用
- Mehta-Shah N, Clemens MW, Horwitz SM, et al. How I treat breast implant-associated anaplastic large cell lymphoma. Blood. 2018. PMID: 30209119. doi:10.1182/blood-2018-03-785972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。